SCHEMBL10053685

SCHEMBL10053685

COC(=O)Cc1ccc(OCc2nc(C)c(C)nc2C)c(OC)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.45
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
LMNA P02545 5/20 0.45
ABL1 P00519 1/20 0.44
RIN1 Q13671 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MAPK1 P28482 3/20 0.44
KDM4E B2RXH2 1/20 0.44
TSHR P16473 1/20 0.44
MAPK10 P53779 1/20 0.44
EPHX2 P34913 1/20 0.43
NPC1 O15118 2/20 0.43
HTT P42858 1/20 0.43
KLK7 P49862 1/20 0.43
ESR1 P03372 1/20 0.43
THRA P10827 1/20 0.43
THRB P10828 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28235970 0.83 RAB9A (0.60) GAAKMT2AMEN1MAPTHPGD
SCHEMBL28237153 0.81 RAB9A (0.44) KMT2AMEN1MAPTHPGDLMNA
SCHEMBL583233 0.80 KMT2A (0.54) KMT2AMEN1MAPTHPGDLMNA
SCHEMBL583633 0.79 HTT (0.61) HPGDSMN1; SMN2TSHRNPC1HTT
SCHEMBL198282 0.78 ALDH1A1 (0.62) GAAKMT2AMEN1MAPTHPGD
SCHEMBL29626821 0.78 ALDH1A1 (0.62) GAAKMT2AMEN1MAPTHPGD
SCHEMBL29066085 0.78 MTNR1A (0.62) KMT2AMEN1HPGDSMN1; SMN2KDM4E
SCHEMBL19926092 0.78 HTT (0.58) GAAMAPTLMNASMN1; SMN2NPC1
SCHEMBL29874847 0.78 HTT (0.58) GAAMAPTLMNASMN1; SMN2NPC1
SCHEMBL18887599 0.77 TSHR (0.56) GAAMAPTHPGDLMNAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350033-B2 4-((3, 5, 6-trimethylpyrazine-2-yl) methoxyl) benzoic acid and its derivatives ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) 2013-01-08 US disclosed
EP-2213666-B1 LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION LI JIAMING (CN) 2012-02-15 EP disclosed
US-20100228029-A1 Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application ANHUI UNIVERSITY OF CHINESE MEDICINE (CN) 2010-09-09 US disclosed
EP-2213666-A1 LIGUSTRAZINE AROMATIC ACID ETHER DERIVATIVE, ITS PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION Li, Jiaming (CN) 2010-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228029-A1 Ligustrazine aromatic acid ether derivative, its preparation method, pharmaceutical composition, and application AHR, CYP3A5, CYP3A43 GAA 2636/4885KMT2A 1254/4885MEN1 4678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.